Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and can lead to life-threatening complications like hepatic carcinoma and cirrhosis. Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist antidiabetic drug, has the capacity to overcome insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shan, Wang, Xiaoman, Zhang, Jielei, Li, Jingyi, Liu, Xiaogang, Ma, Yuanyuan, Han, Chao, Zhang, Lixia, Zheng, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010322/
https://www.ncbi.nlm.nih.gov/pubmed/29924135
http://dx.doi.org/10.1590/1414-431X20187299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010322/
https://www.ncbi.nlm.nih.gov/pubmed/29924135
http://dx.doi.org/10.1590/1414-431X20187299

Ejemplares similares